Abiomed (ABMD) Tops Q1 EPS by 12c

Abiomed (NASDAQ: ABMD) reported Q1 EPS of $0.20, $0.12 better than the analyst estimate of $0.08. Revenue for the quarter came in at $73.4 million versus the consensus estimate of $66.27 million.

Abiomed sees FY2015 revenue of $300-310 million, versus prior guidance of $285-295 million and the consensus of $292.4 million.

For earnings history and earnings-related data on Abiomed (ABMD) click here.

You May Also Be Interested In

• Meta capex to surge in 2027, neocloud fears ’erroneous’ - SemiAnalysis
• Morgan Stanley turns cautious on freight stocks despite stronger cycle outlook
• ArcelorMittal (MT:NA) (MT) PT Raised to EUR65 at Jefferies